Precision oncology is premised on large-scale, annotated 'omics data that improve our understanding of mutations, treatment response, resistance, quality of life and side effects, within an LHS.
Confronted with value uncertainty and high patient demand, payers are considering managed access approaches that re-evaluate adopted technologies or that manage the risk of early patient access through risk-sharing arrangements between developers and healthcare systems.
Patients with advanced Hodgkin’s Lymphoma (HL) have been with the combination of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and have largely positive outcomes.
Stereotactic ablative radiotherapy (SABR) may offer potential benefit for patients with oligometastatic cancers. The SABR technology is still evolving, and there is still uncertainty about whether or not this treatment will be effective.
Detecting prostate cancer early in men at risk is of prostate cancer can potentially improve outcomes. Prostate specific antigen (PSA) testing, however, has been shown to not be an effective method of detecting prostate cancer in the population.
It is known that ultraviolet light exposure causes melanoma. However, it is not clear whether there are other environmental factors acting along with ultraviolet radiation. This study investigates the role of organochlorine compounds, found in the environment, in melanoma development.
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.